Full-Scale Expansion into Human-Derived Biomaterials Business

On July 14, CJ MedTec announced that, together with CJ Bio, it will expand its extracellular matrix (ECM) platform technology to the adipose tissue sector and actively pursue the development and global commercialization of next-generation medical biomaterials based on human-derived adipose tissue.


Exterior of CJ MedTech. CJ MedTech

Exterior of CJ MedTech. CJ MedTech

View original image

The core of this initiative is not adipose tissue itself, but the ECM platform technology that can be applied to various human tissues and bio-derived materials. CJ Bio Group possesses a platform technology that removes cellular components that can trigger immune responses according to the characteristics of the source tissue, and stably isolates and purifies high-purity ECM required for tissue regeneration. Through this, the company has secured technological competitiveness that enables the development of various source materials—such as skin, adipose tissue, and fish-derived materials—into medical biomaterials.


The extracellular matrix (ECM) is a biological substrate that supports tissue structure and plays a critical role in cellular growth and function. Based on this ECM platform technology, CJ Bio Group plans to continuously expand its lineup of next-generation biomaterial products that can be applied not only to reconstruction and soft tissue augmentation, but also to a wide range of medical fields.


The adipose-derived ECM product being developed removes cellular components from human adipose tissue and utilizes the remaining ECM as a medical material. Both companies announced that they will stably procure raw materials through certified tissue banks, such as those accredited by the American Association of Tissue Banks (AATB), and will establish traceability for donor-specific raw materials, as well as process and quality management systems, to develop medical products with consistent quality.


The companies plan to leverage the unique properties of adipose-derived ECM to expand its application not only in reconstruction and soft tissue defect augmentation, but also in the medical aesthetics sector. Their strategy is to build a product portfolio based on adipose-derived ECM by optimizing target properties, formulations, dosage, and packaging specifications for various clinical needs, rather than restricting themselves to a specific indication or single product.


During the course of the project, CJ Bio will be responsible for ECM source technology and biomaterial research and development, while CJ MedTec will oversee product planning, selection of application sectors, domestic and international regulatory strategies, establishment of production systems, and business commercialization. The two companies plan to organically connect their group-wide capabilities in research and development, GMP manufacturing, quality control, and commercialization to create an integrated value chain from product development to commercialization.


To this end, CJ Bio Group will utilize its key research and manufacturing bases—including Smart Campus, Novo Factory, and Regen Hub—to operate a full-cycle productization system encompassing research and development, process development, quality verification, production, and commercialization.


This initiative is being pursued in response to recent regulatory changes that allow for the medical use of human-derived adipose tissue following the revision of the Waste Management Act. The relevant amended regulations are scheduled to take effect from July 8 next year, and the two companies are preparing by specifying product specifications, raw material sourcing and management standards, manufacturing processes, quality control systems, and domestic and international regulatory strategies. After the law comes into effect, they plan to actively conduct validation procedures for product commercialization—including property optimization, specification setting, and process validation—using human-derived adipose tissue secured in compliance with the relevant laws and bioethics guidelines.


The companies also intend to actively pursue entry into global markets, including the United States. In the United States, products for soft tissue augmentation using ECM derived from donated human adipose tissue have already been commercialized, and the adipose-derived ECM sector is regarded as a field with proven technological and business viability in the global market. CJ MedTec and CJ Bio plan to gradually implement their overseas commercialization strategy, taking into account both the global regulatory environment and market demand.



Hyeonseung Yoo, CEO of CJ Bio and CJ MedTec, stated, "CJ Bio Group possesses platform technology and research and production infrastructure that enables the stable isolation and purification of high-purity ECM from a variety of source tissues for use in medical products. With this expansion of our platform into adipose tissue, we aim to broaden our applications to include not only reconstruction and soft tissue augmentation, but also the medical aesthetics sector, thereby building a next-generation biomaterial portfolio and continuously strengthening our competitive edge in the global market."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing